Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Company profile
Ticker
APVO
Exchange
Website
CEO
Mr. Marvin L. White
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aptevo Research and Development LLC ...
APVO stock data
Latest filings (excl ownership)
8-K
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
18 Sep 24
424B4
Prospectus supplement with pricing info
17 Sep 24
EFFECT
Notice of effectiveness
17 Sep 24
8-K
Other Events
16 Sep 24
S-1
IPO registration
30 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
8 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
7 Aug 24
DEF 14A
Definitive proxy
15 Jul 24
S-8
Registration of securities for employees
12 Jul 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.07 mm | 8.07 mm | 8.07 mm | 8.07 mm | 8.07 mm | 8.07 mm |
Cash burn (monthly) | 728.00 k | 1.08 mm | 2.01 mm | 2.16 mm | 2.05 mm | 2.02 mm |
Cash used (since last report) | 1.98 mm | 2.93 mm | 5.46 mm | 5.88 mm | 5.57 mm | 5.50 mm |
Cash remaining | 6.09 mm | 5.14 mm | 2.61 mm | 2.19 mm | 2.49 mm | 2.56 mm |
Runway (months of cash) | 8.4 | 4.8 | 1.3 | 1.0 | 1.2 | 1.3 |
Institutional ownership, Q1 2024
1.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.08 mm |
Total shares | 122.17 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hirschman Orin | 122.17 k | $5.08 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Aug 24 | Lamothe Jeffrey G. | Common Stock | Option exercise | Acquire M | No | No | 0 | 272 | 0.00 | 1,166 |
8 Aug 24 | Lamothe Jeffrey G. | Common Stock | Option exercise | Acquire M | No | No | 0 | 42 | 0.00 | 894 |
8 Aug 24 | Lamothe Jeffrey G. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 272 | 0.00 | 0 |
8 Aug 24 | Lamothe Jeffrey G. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 42 | 0.00 | 41 |
8 Aug 24 | SoYoung Kwon | Common Stock | Option exercise | Acquire M | No | No | 0 | 213 | 0.00 | 801 |
8 Aug 24 | SoYoung Kwon | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 213 | 0.00 | 0 |
8 Aug 24 | Daphne L Taylor | Common Stock | Option exercise | Acquire M | No | No | 0 | 158 | 0.00 | 576 |
8 Aug 24 | Daphne L Taylor | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 158 | 0.00 | 0 |
17 Jul 24 | Kunz Barbara Lopez | RSU Common Stock | Grant | Acquire A | No | No | 0 | 925 | 0.00 | 925 |
17 Jul 24 | Abdun-Nabi Daniel | RSU Common Stock | Grant | Acquire A | No | No | 0 | 925 | 0.00 | 925 |
News
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
17 Sep 24
Watching Shares Of Aptevo Therapeutics; Traders Circulating Zacks Investment Research Article Titled, "Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know"; Shares Seeing Volume
15 Aug 24
Aptevo Therapeutics Q2 EPS $(1.67) Beats $(3.92) Estimate
8 Aug 24
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
18 Jul 24
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
18 Jul 24
Press releases
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
18 Sep 24
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
16 Sep 24
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
16 Sep 24
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
13 Sep 24
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
13 Aug 24